Revised SPC: ViePax XL 225 mg Prolonged-Release Tablets
SPC now notes that observational data indicate an increased risk of postpartum haemorrhage following SSRI/SNRI exposure within the month prior to birth. Manufacturers advise it must only be given in pregnancy if the expected benefits outweigh any possible risk.
Source:
electronic Medicines compendium